Hims & Hers brings former Amazon executive into C-suite
Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped establish many of its health-care offerings, will join the telehealth company as its chief operations officer.
Kabbani spent nearly 20 years at Amazon, where he oversaw the launch of Amazon Pharmacy, the company's acquisition of PillPack and its global Covid-19 Vaccination Task Force. He also helped stand up Amazon Kindle, Amazon Logistics, Amazon Music and Prime Video services.
Hims & Hers offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss. The company, which saw revenue increase by 69% last year, said Kabbani will help the company continue to grow and scale.
"Nader's experience scaling operations at the highest level makes him uniquely qualified to help us build the future of healthcare," Hims and Hers CEO Andrew Dudum said in a statement.
In addition to his experience at Amazon, Kabbani also held executive leadership roles at the supply chain logistics company Flexport and the warehouse automation company Symbotic.
Hims & Hers shares had a volatile start to the year, notching several double digit moves over the last few months. Investors have been paying close attention to the company's weight loss offering, which was thrown into question after the U.S. Food and Drug Administration announced changes to the medication supply environment earlier this year.
Shares of the company closed up 23% on April 29, for instance, after Novo Nordisk said it would offer its weight loss drug Wegovy through telehealth providers like Hims & Hers.
The stock was down more than 1% on Monday but was up more than 70% year to date.
Hims & Hers is slated to report earnings after market close.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
29 minutes ago
- Miami Herald
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Axios
2 hours ago
- Axios
Starbucks taps into health trends with protein coffee test
LAS VEGAS — Starbucks is tapping into the growing demand for protein-packed drinks as consumers seek to boost their intake for health and wellness. Why it matters: The world's largest coffee chain unveiled Tuesday that it is testing protein in its cold foam as part of its "Back to Starbucks" plan. CEO Brian Niccol is trying to reverse a decline in foot traffic and sales by returning to its roots. The big picture: Protein is hot and having a moment beyond social media influencers sharing order hacks. Restaurant brands like Dutch Bros Coffee and Smoothie King have added more protein to their products to cater to changing consumer appetites. Eating a high-protein diet is important to maintain muscle for people taking appetite-suppressing injectable treatments like Ozempic and Wegovy, research shows. Nearly 18 million Americans are expected to be taking versions of GLP-1 drugs by 2029, according to investment bank UBS. Zoom in: Niccol told Axios in an interview Tuesday that the protein cold foam being tested is for a number of different consumer groups including 20-year-old males, 50-year-old females and people taking GLP-1s. "I was watching people coming to our stores, they would get three shots of espresso over ice," Niccol said. "And in some cases, they pull their own protein powder out of their bag, or in other cases, they have a protein drink, like a Fair Life and they'd pour that into their drink." "I'm like, well, wait a second, we can make this experience better for them," he said. "The good news is now I think we're right on trend, and we can do it I think arguably better than anybody else." Flashback: Starbucks had protein smoothies in the past and launched its Vivanno shakes in 2008. They were discontinued in 2018. The company also launched a protein drink in the U.K. last year. The intrigue: Starbucks said the protein powder should be able to be added to any of its cold foam flavors. What's next: Starbucks is testing protein cold foam in five locations in the U.S. under its Starting Five model.
Yahoo
2 hours ago
- Yahoo
Constellation Energy Stock (CEG) Eyes Atomic Expansion to Empower AI Boom
Constellation Energy Corporation (CEG) and Meta Platforms (META) are forming an unlikely partnership. The large-cap energy provider struck what's known as a 'power purchase agreement' with Meta, granting the tech conglomerate the entire 1.1 gigawatt output from Constellation's Clinton Clean Energy Center in Illinois for 20 years starting in mid-2027. Constellation's stock surged around 10% following the news, but has since given up its gains. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The deal marks a shift in how hyperscale tech companies are addressing their AI-driven power needs, with nuclear energy emerging as a preferred solution due to its carbon-free baseload power. Constellation's fleet of nuclear power plants bodes well for future deals, leaving me cautiously optimistic despite a frothy valuation. Meta's 20-year power agreement marks the largest in a growing wave of partnerships between nuclear energy providers and major tech companies. Amazon (AMZN), Microsoft (MSFT), and Google (GOOGL) have all secured nuclear energy to meet the surging power demands driven by their AI initiatives. Nuclear power offers several key advantages over other energy sources, including around-the-clock availability, scalability, and zero carbon emissions. These attributes make it especially appealing to energy-intensive data centers that operate continuously. To put this into perspective, a single ChatGPT query is estimated to consume roughly 10 times more energy than a standard Google search. Nuclear energy remains somewhat misunderstood. While rare nuclear accidents tend to dominate headlines and shape public perception, support for nuclear power is growing. A recent Pew Research Center poll found that 56% of Americans now favor expanding atomic energy. Regulatory momentum is also shifting in its favor, creating a supportive environment for companies like Constellation Energy. The ADVANCE Act of 2024, for example, reduced regulatory review fees for advanced reactor applicants and imposed an 18-month deadline for the Nuclear Regulatory Commission (NRC) to make decisions. Earlier this year, the Trump administration issued executive orders aimed at quadrupling U.S. nuclear capacity by 2050. Constellation, which operates the largest nuclear fleet in the country with 21 reactors across 15 sites, is well-positioned to benefit. When you combine favorable policy shifts with rising demand for energy, particularly from AI infrastructure, it's clear why Constellation is increasingly optimistic about the road ahead In its first quarter earnings, Constellation highlighted the demand for power from data centers. Constellation is just beginning to monetize AI-driven energy demand. Its adjusted operating earnings grew 17.6% in the first quarter to $2.14 per share. Nuclear production maintained an impressive 94.1% capacity factor and continues to remain stable across all geographies. Due to recent deals, Constellation now projects adjusted operating earnings growth of 13% or more through 2030, up from 10%. That said, much of Constellation's potential appears to be priced in. The stock has surged 380% over the past three years and now trades at a Price-to-Earnings (P/E) ratio of 33, nearly double the average for the Utilities sector. This premium valuation leaves little room for error; any operational setbacks could trigger a sharp pullback. While signing long-term agreements with companies like Meta is a positive step, the real challenge lies in execution—building infrastructure, scaling capacity, and navigating regulatory approvals. Time is a critical factor, and delays could have material consequences. Although Constellation currently enjoys a first-mover advantage, it won't be alone for long. Other utility providers are beginning to adopt similar strategies, and competitive pressures in the space are likely to intensify going forward. On Wall Street, CEG sports a Moderate Buy consensus rating based on eight Buy, five Hold, and zero Sell ratings in the past three months. CEG's average stock price target of $318.36 implies an upside potential of approximately 6.5% over the next twelve months. Following the Meta deal, analyst Ryan Levine from Citi downgraded CEG to Hold with a price target of $318. He noted that the stock's rally following the Meta announcement prompted a reevaluation of its value. He added, 'The Meta deal introduces a new framework where nuclear license extensions are considered additive generation, potentially impacting future deals for other plants in CEG's portfolio.' So, Levine sees both positives (a validated business model and premium pricing) and negatives (high valuation, execution risks, and market uncertainty). Technological advancements—particularly in artificial intelligence—present a significant opportunity for utility companies, and Constellation is well-positioned to capitalize. Its extensive fleet of nuclear power plants gives it a strategic edge, and its recent agreement with Meta could serve as a blueprint for future partnerships with other tech giants. Regulatory momentum is also working in Constellation's favor, further strengthening its long-term prospects. That said, the stock is already trading at a premium, reflecting high investor expectations. While Constellation's growth profile justifies a higher valuation—it's far from a traditional, slow-growth utility—there are still meaningful execution risks tied to complex nuclear infrastructure projects. Given this backdrop, a cautiously optimistic outlook, like the one expressed by analyst Levine, may be the most prudent approach. Still, Constellation appears well-positioned to benefit from the broader resurgence of nuclear energy, particularly as AI continues to drive up demand for reliable, carbon-free power, making it a compelling speculative opportunity. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
